Ipratropium bromide intranasal - Chiesi

Drug Profile

Ipratropium bromide intranasal - Chiesi

Alternative Names: RinoAtem; RinoAtem Aqua

Latest Information Update: 08 Jun 2010

Price : $50

At a glance

  • Originator Chiesi
  • Class Antiasthmatics; Antibronchitics; Atropine derivatives; Bronchodilators; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease; Rhinitis

Most Recent Events

  • 08 Jun 2010 No development reported - Phase-III for Rhinitis in Italy (Intranasal)
  • 08 Jun 2010 No development reported - Preregistration for Chronic obstructive pulmonary disease in Italy (Intranasal)
  • 08 Jun 2010 No development reported - Preregistration for Asthma in Italy (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top